Over the last decade, immune checkpoint inhibitors (ICIs), particularly inhibitors of the anti‐programed cell death 1 (PD‐1) and anti‐programed cell death 1 ligand 1 (PD‐L1) axis, have demonstrated exceptional therapeutic landscape in NSCLC.11, 12, 13, 14. This evidence concerns the gene CD274 and non-small cell lung carcinoma.